Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • Historically, the company has been releasing figures that are above expectations.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 16.05 USD
Weaknesses
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
CARA THERAPEUTICS, INC.19.50%902
GILEAD SCIENCES, INC.7.71%79 454
VERTEX PHARMACEUTICALS-12.08%54 017
WUXI APPTEC CO., LTD.0.64%52 082
REGENERON PHARMACEUTICALS-7.53%46 800
BEIGENE, LTD.11.93%26 493
BIONTECH SE16.72%22 911
GENMAB A/S-21.84%20 420
ARGENX SE-1.24%15 628
HUALAN BIOLOGICAL ENGINEERI..-1.87%11 734
MIRATI THERAPEUTICS, INC.-17.59%9 165
NEUROCRINE BIOSCIENCES, INC..-3.00%8 734
ULTRAGENYX PHARMACEUTICAL I..-14.30%7 942
FATE THERAPEUTICS, INC.-8.57%7 797
ASCENDIS PHARMA A/S-13.99%7 747
ACCELERON PHARMA INC.-0.03%7 744
More Results
Financials (USD)
Sales 2021 32,2 M - -
Net income 2021 -91,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,33x
Yield 2021 -
Capitalization 902 M 902 M -
Capi. / Sales 2021 28,0x
Capi. / Sales 2022 9,07x
Nbr of Employees 80
Free-Float 83,8%
Upcoming event on CARA THERAPEUTICS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes